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Abstract
Background: The association between psoriasis and membranous nephropathy (MN) remains largely unclear. We
examined the prevalence of serum PLA2R antibody and characterized the expression of PLA2R and THSD7A in
glomeruli in patients with MN and psoriasis.
Methods: A total of 24 patients with MN without evidence of a secondary cause except psoriasis were enrolled.
The clinical and pathological features were retrospectively analyzed. Serum anti-PLA2R antibody was measured
using IFA Mosaic. Renal tissue samples stored in the laboratory bio-bank were used for PLA2R staining under
immunofluorescence microscopy and THSD7A immunohistochemical analysis.
Results: Twenty-four patients (21 male and 3 female) with a mean age of 43.6 ± 15.7 years old were enrolled.
Serum anti-PLA2R antibody was positive in 7 patients, which was significantly lower than the positivity observed in
idiopathic MN (29.2% vs. 81.7%, P < 0.001). Glomerular PLA2R staining was positive in 7 patients with positive serum
anti-PLA2R antibody. THSD7A staining was negative in all 24 patients. During the follow-up visits, 13 patients with
negative serum PLA2R antibody achieved CR. In contrast, CR was only achieved in 1 patient with positive serum
PLA2R antibody, PR was achieved in 2 patients.
Conclusions: The prevalence of serum anti-PLA2R antibody and glomerular expression of PLA2R was significantly
lower in patients with psoriasis and MN than in those with idiopathic MN, and THSD7A staining was negative,
suggesting that MN is associated with psoriasis in the majority of patients. However, idiopathic MN might also
accompany psoriasis in a minority of psoriatic patients with positive serum anti-PLA2R antibody.
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Background
Membranous nephropathy (MN) is a renal disease
characterized by subepithelial immune deposits in the
glomerulus and is the common cause of nephrotic syn-
drome in adults. MN has been classified as idiopathic
MN and secondary MN associated with other diseases
[1]. In 2009, M-type phospholipase A2 receptor (PLA2R)
was first reported as a major target antigen for
idiopathic MN, and serum autoantibodies to PLA2R can
be detected in 70% of patients with idiopathic MN [2].
Thrombospondin type-1 domain-containing 7A (THSD7A)
was recently reported as another new target antigen for
idiopathic MN, and anti-THSD7A antibodies were positive
in the serum of 8-14% patients with idiopathic MN without
anti-PLA2R antibodies [3]. Both anti-PLA2R and anti-
THSD7A antibodies have been suggested as potential
markers for differentiating idiopathic and secondary MN.
Psoriasis is a common chronic inflammatory disorder
of the skin, affecting 2% of the population in western
countries and 0.47% of the population in China [4–6].
Psoriasis is typically limited to the skin; however,
increasing evidence suggests that this condition is asso-
ciated with systemic disorders, including arthritis, car-
diovascular disease, metabolic syndrome, cancer, Crohn’s
disease, and diabetes mellitus [7, 8].
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An association between kidney disease and psoriasis has
also been proposed [9]. A population-based cohort study
reported that psoriasis was associated with an increased
risk of chronic kidney disease (CKD) independently of
traditional risk factors [10]. However, only isolated cases
of psoriatic-associated MN have been reported thus far
[10–14], and it is not clear whether MN is associated with
psoriasis. To our knowledge, there are currently no
published studies on the prevalence of serum PLA2R
antibodies and the glomerular expression of PLA2R and
THSD7A in patients with psoriasis and MN.
In the present study, we evaluated 24 cases of renal
biopsy-confirmed MN in patients with psoriasis to
examine the prevalence of serum PLA2R antibodies and




In this retrospective study, we reviewed the records of
patients who underwent native renal biopsy between
2003 and 2013 at the National Clinical Research Center
of Kidney Diseases, Jinling Hospital, Nanjing University
School of Medicine. A total of 33 patients showed
biopsy-confirmed MN and psoriasis. Among these indi-
viduals, 5 patients with positive anti-nuclear autoanti-
bodies (ANA) and 4 patients with hepatitis B virus
(HBV) infection were excluded. A total of 24 patients
with MN without evidence of a secondary cause, except
psoriasis, were enrolled in the present study. This study
was approved through the Ethics Committee of Jinling
Hospital, Nanjing University School of Medicine.
Diagnosis of psoriasis
We reviewed the records of the psoriatic patients to
confirm that typical skin lesions of psoriasis had been
described, including red macules and papules with
adherent silvery scales, the thin film phenomenon, and
the dot hemorrhage phenomenon. At least one derma-
tologist at Jinling Hospital made diagnosed the psoriasis.
Psoriasis Area Severity Index (PASI) scores were not
available.
Clinical characteristics
Gender, age, duration of psoriasis and kidney disease,
body mass index (BMI), hypertension, and diabetes mel-
litus were recorded. A BMI ≥25 kg/m2 but <28 kg/m2
was defined as overweight, and a BMI ≥28 kg/m2 was
defined as obesity.
Urine protein excretion for 24 hours, urinary sediment
red blood cell counts, urinary N-acetyl-β-D glucosamini-
dase (NAG) enzyme, and urinary retinol-binding protein
(RBP) were recorded.
The following blood parameters were also recorded, in-
cluding serum creatinine; albumin; cholesterol; triglycer-
ides; hemoglobin (Hb; anemia was defined as Hb <12 g/dl
in men and <11 g/dl in women); serum C3, C4, and
rheumatoid factor (RF); serum ANA, anti-double-stranded
DNA antibody (A-dsDNA); serum HBV markers; anti-
HCV antibodies; anti-PLA2R antibody, measured using IFA
Mosaic (EUROIMMUN AG, Lübeck, Germany); and the
CKD Epidemiology Collaboration (CKD-EPI) creatinine
equation was used to estimate the glomerular filtration rate
(eGFR) [15]. The serum anti-PLA2R antibody was tested
using the serum collected at the time of renal biopsy.
Pathological characteristics
A percutaneous renal biopsy was performed. All cases
were processed using light, immunofluorescence and elec-
tron microscopy. The renal biopsy procedure was speci-
fied as follows: the samples were sectioned at 1.5 μm after
embedded in paraffin, followed by hematoxylin-eosin,
periodic acid-Schiff, periodic acid-silver methenamine
(PASM),and Masson staining. More than 10 glomeruli
were observed under light scope in each renal tissue
sample. The samples were sectioned under frozen condi-
tions and cut at 4 μm for immunofluorescence staining,
followed by staining for IgG, IgA, IgM, C3, C1q, κ and
λ-light chain using polyclonal FITC-conjugated antibodies.
The deposits, staining intensity, and distribution were
observed. The electron microscopy observations were
performed using a Hitachi 7500 electron microscope.
The indirect immunofluorescence assay of deposits of
IgG subclasses was performed as previously reported
[16]. The slides prepared under frozen conditions were
dried, sealed with 10% fetal serum, followed by rinsing
with PBS for 5 minutes. The primary mouse anti-human
IgG1, IgG2, IgG3 and IgG4 monoclonal antibodies
(clone 8c/6-39, HP-6014, HP-6050 and HP-6025, Sigma-
Aldrich) were diluted 1:400 and added, followed by
culturing for 2 hours. FITC-labeled rabbit anti-mouse
IgG secondary antibody (1:50; DAKO) was added after
rinsing the slides with PBS for 5 minutes, and then
cultured for 30 minutes. The slides were dried and
sealed with glycerin, and observed under a fluorescence
microscope. The immunofluorescence intensity of the
IgG subclasses was graded as negative, 1+, or 2 + .
PLA2R staining was performed for all patients using the
renal tissue samples stored in our bio-bank. The biopsies
were stained for subsequent immunofluorescence analysis
of the pronase-digested paraffin sections using rabbit anti-
PLA2R as the primary antibody (Sigma-Aldrich) and
polyclonal goat anti-rabbit IgG (Life Technologies) as the
secondary antibody. Glomerular THSD7A expression was
observed through immunohistochemical analysis accord-
ing to the methods of Tomas et al. [3]
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Outcomes
Remission of MN was defined according to 2012
KDIGO guidelines [17]. A complete remission (CR) was
defined as a urine protein <0.5g/24h, a partial remission
(PR) was defined as a urine protein of 0.5-3.5g/24h with
≥50% reduction compared with baseline. Patients who
did not meet the definitions of CR or PR were assigned
to no response (NR).
Statistical analysis
Continuous variables are expressed as the means ± the
standard error or median. Differences between the
groups were analyzed using Student’s t-test. The qualita-
tive data were analyzed using the chi-square (χ2) or
Fisher’s exact test, as indicated and expressed as percent-
ages. The reported p-values were two-sided, and a p-value
< 0.05 was considered statistically significant. All the
analyses were performed using SPSS software (version
18.0, SPSS Inc., USA).
Results
General clinical information
The present study enrolled 24 patients (21 male and 3
female) with a mean age of 43.6 ± 15.7 years old (ran-
ging from 17 to 69), a median duration of psoriasis of 72
(4-480) months, and a median duration of kidney disease
of 2 (0.3-108) months. All 24 patients presented with
psoriasis vulgaris. Psoriasis vulgaris occurred before the
onset of kidney disease in 23 patients. Psoriasis vulgaris
and MN were diagnosed at the same time in only 1
patient. Interestingly, among the 18 patients with a
detailed BMI record, 6 patients were obese and 4 patients
were overweight. In addition, 5 of the 24 patients were
diagnosed with diabetes mellitus, 9 patients were diag-
nosed with hypertension, and 3 patients were diagnosed
with anemia. The general characteristics of the patients at
renal biopsy are listed in Table 1.
All patients were negative for ANA, A-dsDNA and RF.
C3 was decreased in 4 patients, and C4 was normal in
all patients. The urinary markers of renal tubular injury
were also observed. NAG enzyme was increased in 20
patients, and RBP was increased in 14 patients.
Pathologic manifestation
The pathological characteristics of the patients are
shown in Fig. 1. Stiff glomerular peripheral capillary
loops, subepithelial fuchsinophilic deposits, and thicken-
ing of glomerular basement membrane were observed
under light microscopy. Atypical MN with mesangial
proliferation was observed in 23 patients (mild prolifera-
tion in 20 patients and moderate in 3 patients). A total
of 16 patients showed a few infiltrating cells in glom-
eruli, including monocytes and/or neutrophil granulo-
cytes, and 15 patients had mild tubulointerstitial fibrosis,
13 patients had acute tubular injury, and 18 patients had
focal concentrations of infiltrated monocytes, neutrophil
granulocytes and plasma cells. Hyaline degeneration of
the interstitial small artery was observed in 12 patients
(9 patients with hypertension and 3 patients without).
The findings from immunofluorescence and electron
microscopy analyses are listed in Table 2. Granular de-
posits of IgG and C3 along the capillary loop of the
glomeruli were observed in all the patients. Codeposits
of C1q were positive in 11 patients. Positivity for IgG,
IgA, IgM, C3, and C1q were present in 4 patients. The
immunofluorescence staining of IgG subclasses was also
performed. Deposits of IgG1, IgG2, IgG3 and IgG4 were
observed in 4 patients, deposits of IgG1, IgG2 and IgG4
were observed in 13 patients, and deposits of IgG1 and
IgG4 were observed in 6 patients. In the 7 patients with
PLA2R positive MN, 5 patients had IgG4 predominant
staining in biopsy, 1 patient had equal fluorescence
intensity of IgG1 and IgG4 staining, and 1 patient had
no glomeruli under immunofluorescence staining.
The detailed characteristics were recorded under elec-
tron microscopy in 20 patients, showing that 4 patients
were classified as stage I MN, 8 patients were classified
as stage II MN and 8 patients were classified as stage III
MN. In addition to subepithelial electron-dense deposits,
electron-dense deposits in the mesangium were ob-
served in 9 patients. The effacement of foot processes in
podocytes was observed in all patients.
Serum anti-PLA2R antibody and glomerular expression of
PLA2R and THSD7A
Serum anti-PLA2R antibody was positive in only 7 of
the 24 patients, a result significantly lower than that ob-
served in idiopathic MN in a previous report (29.2% vs.
81.7%, P < 0.001) [18].
The glomerular expression of PLA2R and THSD7A
was observed through immunofluorescence staining and
immunohistochemical analysis, respectively (Fig. 2).
PLA2R was positive in the glomeruli of 7 patients whose
serum PLA2R antibody was positive, which is signifi-
cantly lower than that in patients with idiopathic MN, as
reported previously [19] (29.2% vs 69.3%, P = 0.001).
THSD7A was negative in all 24 patients.
We compared the clinical characteristics between pa-
tients with serum PLA2R antibody and patients without
PLA2R antibody. There was no significant difference in
proteinuria, serum albumin, serum creatinine, and eGFR.
Treatment and prognosis
The treatments for psoriasis prior to renal biopsy in-
cluded oral steroids in 3 patients, and oral Tripterygium
wilfordii Hook F (TwHF) in 2 patients. The remainder
of the patients had used topical treatments, such as cor-
ticosteroids, vitamin D analogs, and sulfur ointments; no
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NSAIDs, cyclosporin A, methotrexate,D-penicilliamine,
or gold salts were used in these patients.
Treatment and prognosis information for MN was
available for 19 patients, and 5 patients were lost during
the follow-up visits (Table 1). A total of 10 patients were
treated with TwHF, while 7 patients were treated with
TwHF plus prednisone (Pred) at 30 mg per day, and 2
patients were treated with tacrolimus.
CR was achieved in 14 (73.7%) patients (8 patients
were treated with TwHF, 4 patients were treated with
TwHF plus Pred, and 2 patients were treated with tacro-
limus). PR was achieved in 2 (10.5%) patients (1 patient
was treated with TwHF and 1 patient was treated with
TwHF plus Pred). NR was observed in 3 (15.8%) patients
who received TwHF plus Pred, including 1 patient who
progressed to end stage renal disease after 12 months
treatment with TwHF.
Interestingly, we also observed that in the 17 patients
with negative serum PLA2R antibody, 13 patients
achieved CR and 4 patients were lost. In contrast, in the 7
patients with positive serum PLA2R antibody, CR was
achieved in only 1 patient, PR was achieved in 2 patients,
NR was in 3 patients, and 1 patient was lost during the
follow-up visits. Unfortunately, the prognosis of psoriasis
was not quantitative evaluated because PASI scores were
not available at baseline and follow-up visits. However, we
indeed observed the significant improvements in skin
lesions in patients 2, 10, 11, 16, who achieved CR in
proteinuria after the TwHF or Pred + TwHF treatment.
The detailed outcomes of psoriasis in other patients were
not available during follow-up visits.
Discussion
MN is classified as either idiopathic or secondary to
various underlying diseases, such as autoimmune dis-
eases, viral hepatitis, malignancies, or exposure to toxins
or drugs. The M-type PLA2R and THSD7A have been
identified as major target podocyte antigens involved in
adults with idiopathic MN, and serum anti-PLA2R anti-
bodies have a high sensitivity and specificity for idio-
pathic MN [2, 3, 18, 20–22]. Although MN associated
with psoriasis has also been documented in case reports,
describing improvements in both MN and skin lesions
in psoriatic patients and the complete remission of
Table 1 Clinical findings at biopsy and follow-up visits in patients with psoriasis and membranous nephropathy

















1 M 36 36 3.95 1 29.7 0.64 143.95 - Pred + TwHF CR
2 M 60 4 7.71 1 29.9 0.87 107.95 - TwHF CR
3 M 12 2 2.9 1 37.9 0.85 122.82 - TwHF CR
4 F 96 48 1.11 1 39.3 0.73 118.94 - FK506 CR
5 M 24 2.33 5.97 35 21 0.61 138.79 - TwHF,CsA CR
6 M 36 12 0.74 1 45.9 0.9 109.49 - TwHF CR
7 F 84 2 5.44 1 21.2 0.52 126.83 - NA LOST
8 M 60 2 4.78 1 21.9 1.31 55.16 - NA LOST
9 F 120 3 0.59 1 38.7 0.48 128.39 - Pred + TwHF CR
10 M 12 2 9.3 1 25.9 0.73 114.41 - TwHF CR
11 M 180 6 7.43 1 24.6 1.31 64.38 - Pred + TwHF CR
12 M 4 1.33 4.91 34 23.5 0.71 100.55 + TwHF ESRD
13 M 12 1 4.24 1 24.1 1.09 89.33 + Pred + TwHF PR
14 M 120 0.33 4.96 1 21.7 0.81 112.74 - Pred + TwHF CR
15 M 240 108 8.29 1 25.4 1.01 81.04 + TwHF PR
16 M 24 2 2.5 1 37.9 0.68 110.58 - TwHF CR
17 M 216 2 0.63 1 44.9 0.85 108.23 - TwHF CR
18 M 360 1 1.09 27 37.7 0.91 89.38 + TwHF CR
19 M 48 3 5.23 1 30.7 0.8 122.43 + Pred + TwHF NR
20 M 120 15 9.42 1 17.8 2.18 31.97 + Pred + TwHF NR
21 M 60 0.3 8.42 74 19.2 1.55 51.43 + NA LOST
22 M 240 0.25 5.47 8 20.5 1.12 76.18 - FK506 + Pred CR
23 M 480 1 8.67 10 19.8 1.02 75.7 - NA LOST
24 M 480 4 6.02 1 18.8 2.09 32.94 - NA LOST
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proteinuria and skin symptoms after the successful treat-
ment of psoriasis, there have been no studies concerning
the glomerular expression of PLA2R and THSD7A in
patients with psoriasis and MN. Thus, the association of
psoriasis and MN remains uncertain.
The present study was the first to examine the preva-
lence of serum PLA2R antibodies and characterize the
glomerular expression of PLA2R and THSD7A in pa-
tients with psoriasis and MN. The findings showed only
7 patients with positive serum anti-PLA2R antibody and
glomerular PLA2R expression, which was significantly
lower than that observed in patients with idiopathic MN
[18]. The anti-PLA2R antibody was measured using IFA
Mosaic in the present study, while it was measured using
western blot in the previous study. Although different
assays may have different sensitivity and specificity, a
series of studies have confirmed the concordant results
of anti-PLA2R antibody with IFA Mosaic and western
blot methods [23–25]. In addition, we also perform the
PLA2R staining of the renal tissue. Hence, the results of
our present study were reliable and comparable to the
results of our previous reported study. These findings
also indicated that the MN was secondary in a majority
of patients with psoriasis. However, the coincidental oc-
currence of idiopathic MN with psoriasis should be con-
sidered in the patients with serum anti-PLA2R antibody.
Although psoriasis is a common chronic inflammatory
disorder of the skin, increasing evidence has demon-
strated that psoriasis is associated with an increased risk
of CKD and urinary albumin excretion [26, 27]. A
population-based cohort study demonstrated that mod-
erate to severe psoriasis was associated with an increased
risk of CKD, independent of traditional risk factors [10].
In another cross sectional study, Yang et al reported that
renal failure was more prevalent in patients with severe
psoriasis than in age- and sex-matched controls [28]. In
addition, multiple cross-sectional studies had also
observed a greater prevalence of microalbuminuria [26].
Psoriatic nephropathy is recently described. Nephropa-
thy associated with psoriasis has been increasingly
reported in recent years. These kidney diseases include
IgA nephropathy [29, 30], MN [11–14], membrano-
proliferative glomerulonephritis [31], focal segmental
glomerulosclerosis [32], minimal change disease [33], AA-
amyloidosis [34], and therapy-related tubular-interstitial
alteration [26].
In the present study, 24 psoriatic patients were diag-
nosed with MN according to renal pathological findings
and had long-standing psoriasis prior to the appearance
of proteinuria. These patients were never administered
nephrotoxic drugs (such as NSAIDs, gold salts, or
D-penicillamine) or experienced systemic lupus erythe-
matosus (SLE),malignancies,or HBV or HCV infection.
However, immunofluorescence assays showed that 11 of
the 24 patients had granular parietal C1q deposits
associated with IgG in the glomeruli, and 4 of these 11
patients had codeposits of IgA and IgM. C1q is typically
absent or observed at low levels in idiopathic MN,
Fig. 1 Pathologic findings of MN in patients with psoriasis. (a) and (b) Glomeruli with subepithelial fuchsinophilic deposits along the epithelium (PASM
staining and Masson trichrome; original magnification × 400). (c) Glomerular subepithelial electron-dense deposits (arrow) with foot process effacement
(electron micrograph). (d)-(f) Staining for IgG (2+), C3 (2+) and C1q (1+) along the glomerular basement membrane (immunofluorescence staining;
original magnification, ×400)
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whereas it is typically more present in secondary disease
[35]. Thus, it is reasonable to speculate that the patho-
genesis of MN in psoriatic patients differs from the
pathogenesis of idiopathic MN.
Additionally, immunofluorescence staining showed
that variations in the distribution of IgG subclasses
reflect predominant Th1 and Th2 immune responses
[36]. Larsen et al had found that secondary membranous
nephropathy with positive PLA2R1 showed IgG4-
predominant staining, the IgG4 predominance raises the
possibility that these cases are more pathogenically
related to primary membranous nephropathy than sec-
ondary [37]. In this study, glomerular deposits of both
IgG1 and IgG4 were observed in all patients, indicating
that both Th1 and Th2 immune response participated in
the pathogenesis of MN associated with psoriasis. The
immunofluorescence intensity of IgG1 was stronger than
that of IgG4 in 7 of 17 patients with negative serum
PLA2R antibody, in contrast the intensity of IgG4 was
stronger than that of IgG1 in 5 of 7 patients with
positive serum PLA2R antibody. The distribution of
glomerular IgG subclasses further indicated that MN
was secondary in cases of psoriasis with negative serum
PLA2R antibody, and idiopathic MN might also be coin-
cident with the occurrence of psoriasis in patients with
positive serum PLA2R antibody.
The optimal therapeutic management of secondary
MN involves treating the underlying clinical conditions
and diseases implicated in the etiology of MN. In the
present study, the response to treatment with Pred and
(or) TwHF was better in patients with negative PLA2R
antibody than in those with positive PLA2R antibody.
Previous studies have also demonstrated that proteinuria
was decreased after the successful treatment of psoriasis.
The relatively well response to treatment with cortico-
steroids and TwHF also indicated that MN was associ-
ated with psoriasis in patients with negative PLA2R
antibody.
The mechanism underlying the association between
MN and psoriasis remains unclear. Some authors have
suggested that the immunological mechanism respon-
sible for the association between SLE and secondary MN
Table 2 IF and EM findings in patients with psoriasis and membranous nephropathy
Case IF findings Electron microscopy findings








1 1+ 1+ 1+ 1+ 1+ Neg IgG1 1+ , IgG2 1+, IgG4 2+ ND ND ND ND
2 2+ 1+ Neg 2+ Neg Neg IgG1 2+ , IgG2 1+, IgG4 1+ ND ND ND ND
3 1+ Neg 1+ 1+ 1+ Neg IgG1 2+, IgG4 2+ ND ND ND ND
4 2+ 1+ 1+ 2+ Neg Neg IgG1 2+, IgG4 2+ ND ND ND ND
5 2+ 1+ Neg 2+ Neg Neg IgG1 2+ , IgG2 1+, IgG4 2+ + Neg Neg 2
6 4+ 1+ 1+ 2+ 1+ Neg IgG1 2+, IgG4 1+ + Neg Neg 2
7 2+ Neg Neg 1+ Neg Neg IgG1 2+ , IgG2 1+, IgG4 2+ + + + 2
8 2+ Neg Neg 2+ 1+ Neg IgG1 2+ , IgG2 1+, IgG4 1+ + Neg Neg 2
9 2+ 1+ Neg 1+ Neg Neg IgG1 2+, IgG4 2+ + Neg + 3
10 2+ Neg Neg 2+ 1+ Neg IgG1 2+ , IgG2 1+, IgG4 2+ + Neg + 1
11 2+ Neg Neg 2+ 1+ Neg IgG1 2+ , IgG2 1+, IgG4 1+ + + + 1
12 2+ 1+ 1+ 2+ 1+ + IgG1 1+ , IgG2 1+, IgG4 2+ + Neg Neg 3
13 2+ Neg Neg 1+ 1+ + IgG1 1+, IgG2 1+, IgG3 1+, IgG4 2+ + Neg + 3
14 2+ Neg Neg 2+ Neg Neg IgG1 2+, IgG4 1+ + Neg Neg 1
15 2+ Neg Neg 1+ Neg + No glomeruli + Neg Neg 3
16 2+ Neg Neg Neg Neg Neg IgG1 1+ , IgG2 1+, IgG4 2+ + Neg + 2
17 2+ 1+ 1+ 1+ 1+ Neg IgG1 2+ , IgG2 1+, IgG4 1+ + Neg + 3
18 2+ Neg Neg 2+ 1+ + IgG1 1+ , IgG2 1+, IgG4 2+ + Neg Neg 2
19 2+ 2+ Neg 1+ Neg + IgG1 2+ , IgG2 1+, IgG4 2+ + Neg + 3
20 2+ Neg Neg 2+ 1+ + IgG1 2+, IgG2 1+, IgG3 1+, IgG4 3+ + Neg Neg 2
21 2+ Neg Neg 2+ Neg + IgG1 1+, IgG2 1+, IgG3 2+, IgG4 2+ + + + 3
22 2+ Neg 1+ 2+ Neg Neg IgG1 2+, IgG4 2+ + Neg Neg 2
23 2+ Neg Neg 2+ Neg Neg IgG1 3+, IgG2 2+, IgG3 1+, IgG4 2+ + Neg Neg 1
24 2+ Neg Neg 2+ Neg Neg IgG1 2+ , IgG2 1+, IgG4 2+ + Neg Neg 3
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could also be involved in psoriasis [12, 14]. Susceptibility
loci shared between patients with psoriasis and SLE in a
Chinese population has been identified [38]. In addition,
the circulation antigen or immune complexes associated
with psoriasis could also deposit in the subepithelial
space as another potential mechanism for MN associ-
ated with psoriasis. Unfortunately, no antigen associated
with psoriasis and MN has been identified because of
the relatively rare cases. In the present study, although 5
patients with positive ANA were excluded, low C3 levels
were observed in 4 patients, implying that an auto-
immune mechanism might play an important role in the
association between MN and psoriasis.
Psoriasis vulgaris was observed in all the 24 patient-
s,which is the most common psoriasis type in China [5].
Increasing evidence suggests that psoriasis is associated
with diabetes, metabolic syndrome, and cardiovascular
disease, independent of traditional risk factors [39–41].
The results of the present study also indicated that a
high prevalence of obesity, diabetes mellitus and hyper-
tension as additional risk factors, consistent with the
findings of a previous study.
Due to its retrospective nature, this study has several
limitations. First, the severity of psoriasis was not
recorded; therefore, potential associations between the
severity and renal manifestations of psoriasis could not
be analyzed. Second, the treatments and outcomes of
skin lesions were not quantitative analyzed during the
follow-up visits. Although these limitations exist, the
findings of the present study suggest that dermatologists
and nephrologists should be aware of the association
between MN and psoriasis.
Conclusions
In summary, we observed the prevalence of serum
PLA2R antibodies and glomerular expression of PLA2R
and THSD7A in patients with psoriasis and MN. The
lower proportion of positive serum PLA2R antibody and
glomerular expression of PLA2R, negative expression of
THSD7A, pathological manifestation and distribution of
IgG subclasses indicated that MN was associated with
psoriasis in a majority of patients. However, idiopathic
MN might also be coincident with the occurrence of
psoriasis in patients with positive serum PLA2R anti-
body. Thus, it is important for dermatologists and
nephrologists to be aware of the association between
membranous nephropathy and psoriasis. Further studies
are needed to determine the pathogenesis, optimal treat-
ment, and outcomes of membranous nephropathy asso-
ciated with psoriasis.
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A-dsDNA: Anti-double-stranded DNA antibody; ANA: Anti-nuclear
autoantibodies; BMI: Body mass index; CKD: Chronic kidney disease;
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Fig. 2 Expression of PLA2R and THSD7A in glomerular observed under immunofluorescence microscopy. Staining for PLA2R was negative in 17
patients (a), and positive in 7 patients with MN and psoriasis (b). THSD7A was negative in all 24 patients through immunohistochemical analysis
(c), and a positive control is shown in patients with idiopathic MN (d)
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